Journal of Autism and Developmental Disorders

, Volume 25, Issue 3, pp 283–294

Use of methylphenidate in the treatment of children with autistic disorder

Authors

  • Humberto Quintana
    • Western Psychiatric Institute and Clinic
  • Boris Birmaher
    • Western Psychiatric Institute and Clinic
  • Deborah Stedge
    • New York State Psychiatric Institute
  • Susan Lennon
    • New York State Psychiatric Institute
  • Jane Freed
    • New York State Psychiatric Institute
  • Jeffrey Bridge
    • Western Psychiatric Institute and Clinic
  • Larry Greenhill
    • New York State Psychiatric Institute
Article

DOI: 10.1007/BF02179289

Cite this article as:
Quintana, H., Birmaher, B., Stedge, D. et al. J Autism Dev Disord (1995) 25: 283. doi:10.1007/BF02179289

Abstract

The use of psychostimulants in autistic disorder has not received extensive evaluation. Furthermore, their use for the symptomatic control of autistic disorder has been felt to be contraindicated. This study investigates the use of methylphenidate (MPH) for the treatment of selected symptoms of autistic disorder. Ten children, ages 7–11, with a DSM-III-R diagnosis of autistic disorder participated in a double-blind crossover study using placebo and two MPH doses (10 mg or 20 mg bid). Subjects showed modest but statistically significant improvement on MPH over placebo. No significant side effects including worsening stereotypic movements occurred on either dose. Improvement in hyperactivity and lack of adverse effects suggest that MPH may be useful in the treatment of hyperactive autistic children.

Copyright information

© Plenum Publishing Corporation 1995